IL6 and COVID-19: In this contest, among the most promising therapeutic strategies for dampening excessive inflammatory responses and ARDS in SARS-Cov2 infection, tocilizumab, an anti–IL-6R mAb inhibitor that interferes with IL-6–mediated signaling and has already approved for RA treatment (59, 60) resulted effective in preventing the cytokine storm, ARDS and to reduce mortality in COVID-19 patients (61–63).